Idexx Laboratories (IDXX) debt: $450M
Idexx Laboratories had $450M of long-term debt on Dec 31, 2025, including the part due within a year, down 27.2% from $618M a year earlier.
From Idexx Laboratories's filings with the SEC · Read the filing · IDXX stock page
Idexx Laboratories debt by year
#1,160 of 2,129 US companies by debt · See the full ranking
| Year ended | Debt | Change |
|---|---|---|
| Dec 31, 2025 | $450M | -27% |
| Dec 31, 2024 | $618M | -12% |
| Dec 31, 2023 | $698M | -9% |
| Dec 31, 2022 | $770M | -10% |
| Dec 31, 2021 | $851M | – |
Debt of similar companies
Companies in the same industry as Idexx Laboratories, by SEC industry code, with the closest debt. Each name opens the same page for that company.
| Company | Debt, latest year | Year ended |
|---|---|---|
| Curaleaf Holdings | $549M | Dec 31, 2025 |
| INSMED | $547M | Dec 31, 2025 |
| Repligen | $542M | Dec 31, 2025 |
| Idexx Laboratories | $450M | Dec 31, 2025 |
| Pacira BioSciences | $372M | Dec 31, 2025 |
| Mannkind | $355M | Dec 31, 2025 |
| Opko Health | $344M | Dec 31, 2025 |
Questions and answers
What is Idexx Laboratories's debt?
Idexx Laboratories had $450M of long-term debt on Dec 31, 2025, including the part due within a year, down 27.2% from $618M a year earlier.
Numbers as reported in Idexx Laboratories's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology